Skip to main content
. 2022 Mar 24;13:829228. doi: 10.3389/fimmu.2022.829228

Figure 2.

Figure 2

Recipient KLRC2 variant distribution among (A) donor-specific antibody (DSA)+ study patients versus propensity score-matched DSA– control subjects (patients selected from the BORTEJECT trial), and (B) donors versus recipients of the Collaborative Transplant Study (CTS) study cohort. Genotype frequencies in the CTS recipient population deviated from Hardy Weinberg equilibrium (P = 0.008), but not the donor-specific antibody (DSA)+ (P = 0.31), DSA– (P=0.10) and CTS donor cohorts (P = 0.29), respectively.